Dear Editor, A 42-year-old lady was diagnosed to have International Staging System (ISS) stage II IgGλ myeloma in 2007. She achieved a minor response after VAD (vincristine, adriamycin, and dexamethasone) induction, then partial remission after further induction with VTD (bortezomib, thalidomide, and dexamethasone), and finally immunofixation-negative complete remission (CR) after autologous stem cell transplantation (ASCT) in December 2007, which was confirmed by bone marrow examination (Fig. 1a) . She was maintained on thalidomide 50 mg/day. Serial serum protein electrophoresis (SPE) remained negative until December 2009 when SPE and immunofixation of serum (IFX) showed reappearance of IgGλ with the paraprotein level measuring 3.8 g/L. However, she was completely asymptomatic and free of CRAB (hypercalcemia, renal failure, anemia, and bone disease) complications. Moreover, SPE showed that the "recurrent" IgGλ was in a different position on electrophoresis (Fig. 1b) , and hence, a diagnosis of oligoclonal reconstitution was made instead of disease relapse. In the absence of salvage chemotherapy, the low level of IgGλ paraprotein persisted between 3 and 4 g/L until October 2010 when repeat SPE and IFX showed disappearance of paraprotein. The patient remained in immunofixation-negative CR as of October 2012.
We have reported frequent oligoclonal reconstitution, which was associated with superior event-free survival in myeloma patients [1] . The paraproteins in oligoclonal reconstitutions often have an isotype different from the original paraprotein [4] . Recurrence of a paraprotein of the same isotype as diagnosis after achievement of CR will raise the possibility of myeloma relapse, implicating subsequent salvage treatment. Moreover, possibility of relapse is especially valid when the paraprotein emerged at 2 years after ASCT, and became measurable. However, when the "recurrent" paraprotein was reviewed, it occupied a different position on electrophoresis gel, and hence consistent with an oligoclonal reconstitution instead of relapse. Finally, this oligoclonal paraprotein level remained low, and eventually disappeared, thereby confirming an oligoclonal reconstitution instead of relapse.
A better way to confirm if the recurrent paraprotein of the same diagnostic paraprotein as part of disease relapse is to perform two-dimensional gel electrophoresis, which is not available in our institute. Moreover, the diagnosis of "relapse" might have triggered salvage treatment in some centers. Finally, as there are many ongoing clinical trials in myeloma, the detection of relapse is an important end point for event-free or progression-free survival analysis.
Oligoclonal reconstitution is becoming prevalent in this era of targeted therapy in myeloma as the depth of response has been increased. Oligoclonal reconstitution was first reported in patients achieving CR after ASCT prior to the advent of novel agents [5] . However, in myeloma patients receiving induction therapy with novel agents followed by ASCT, as many as 25-33 % of patients were found to develop oligoclonal reconstitution [2, 3] .
In conclusion, oligoclonal reconstitution in myeloma is an important differential diagnosis to relapse, impacts important end points such as CR in clinical trials, and obviates the inappropriate consideration of salvage therapy. It is essential to review the serum protein electrophoresis and immunofixation gels to confirm the status of remission. 
